ImmunityBio, Inc. (IBRX)
7.95
+0.08
(+1.02%)
USD |
NASDAQ |
Sep 02, 16:00
7.96
+0.01
(+0.13%)
Pre-Market: 08:13
ImmunityBio Research and Development Expense (TTM) : 241.79M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 241.79M |
| March 31, 2026 | 235.71M |
| December 31, 2025 | 216.56M |
| September 30, 2025 | 187.92M |
| June 30, 2025 | 187.13M |
| March 31, 2025 | 183.03M |
| December 31, 2024 | 188.14M |
| September 30, 2024 | 204.46M |
| June 30, 2024 | 202.41M |
| March 31, 2024 | 204.45M |
| December 31, 2023 | 230.37M |
| September 30, 2023 | 232.18M |
| June 30, 2023 | 251.40M |
| March 31, 2023 | 257.36M |
| December 31, 2022 | 229.89M |
| September 30, 2022 | 228.79M |
| June 30, 2022 | 210.96M |
| March 31, 2022 | 206.12M |
| December 31, 2021 | 195.96M |
| September 30, 2021 | 164.46M |
| June 30, 2021 | 132.47M |
| March 31, 2021 | 92.38M |
| December 31, 2020 | 64.48M |
| Date | Value |
|---|---|
| September 30, 2020 | 56.23M |
| June 30, 2020 | 51.00M |
| March 31, 2020 | 50.42M |
| December 31, 2019 | 49.78M |
| September 30, 2019 | 49.66M |
| June 30, 2019 | 51.57M |
| March 31, 2019 | 52.52M |
| December 31, 2018 | 53.32M |
| September 30, 2018 | 52.89M |
| June 30, 2018 | 49.40M |
| March 31, 2018 | 44.42M |
| December 31, 2017 | 39.68M |
| September 30, 2017 | 36.36M |
| June 30, 2017 | 33.86M |
| March 31, 2017 | 30.64M |
| December 31, 2016 | 26.55M |
| September 30, 2016 | 23.51M |
| June 30, 2016 | 19.50M |
| March 31, 2016 | 15.36M |
| December 31, 2015 | 11.40M |
| September 30, 2015 | 7.202M |
| June 30, 2015 | 3.372M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.635B |
| Sarepta Therapeutics, Inc. | 783.60M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |